Peptide Therapeutics Forum

Congress Center Basel, 13 -14 September 2018

Chairs
Thomas Vorherr (Novartis Pharma AG, Basel, Switzerland)
Roderich Süßmuth (Technical University of Berlin, Berlin, Germany)

Thursday, 13 September 2018

10.15 Rationalizing the passive membrane permeability of cyclic peptides
Sereina Riniker (ETH Zurich, Zurich, Switzerland)

10.45 Positive allosteric modulators for GABAs
Immanuel Lerner (Pepticom, Jerusalem, Israel)

11.15 Networking break

11.45 Employing electronic and structural constraints to advance peptide leads to therapeutic peptide mimic prototypes
William Lubell (University of Montreal, Montreal, Canada)

12.15 Design of bioactive macrocycles
Andrei Yudin (University of Toronto, Toronto, Canada)

12.45 Lunch break and Industry Symposium

14.15 KEYNOTE LECTURE
Revolutionizing the discovery process of bioactive peptides
Hiroaki Suga (School of Science, The University of Tokyo, Tokyo, Japan)

15.15 Networking break

15.45 Vulnerability of invasive glioma cells to lysosomal membrane instabilisation
Pirjo Laakonen (University of Helsinki, Helsinki, Finland)

16.15 Ena/VASP EVH1 domains as possible anti-metastatic targets addressed by structure-optimized polyproline-II secondary structure mimetics
Ronald Kühne (Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany)
Friday, 14 September 2018

10.45  Unlocking the power of D-peptides  
Brett Welch (Navigen, Salt Lake City, United States)

11.15  Antibody targeted Amanitin Conjugates (ATACs): expanding the ADC Landscape with a new payload targeting RNA Polymerase II  
Christian Lutz (Heidelberg Pharma Research GmbH, Heidelberg, Germany)

11.45  Networking break

12.15  68Ga/177Lu-dotatate as theranostic pair in nuclear medicine  
Maurizio Mariani (Advanced Accelerator Applications (AAA), Torino, Italy)

12.45  Patient-centric combination therapy and sustained peptide drug delivery for metabolic disease  
Ved Srivastava (Intarcia Therapeutics, Boston, United States)

13.15  Lunch break and Industry Symposium

14.45  N-butylpyrrolidinone as green solvent for solid phase peptide synthesis  
John Lopez (Novartis Pharma AG, Basel, Switzerland)

15.15  Potential of cell-penetrating peptides for improved drug delivery  
Ines Neundorf (University of Cologne, Cologne, Germany)

15.45  Networking break

16.15  Drug delivery systems for peptides  
Michael Wagner (Sanofi, Frankfurt, Germany)

16.45  In vitro & In vivo performance criteria of enTRinsic™ dosage form using lipid multi-particulates for oral peptide targeted delivery  
Paolo Botti (Lonza, Basel, Switzerland)

The programme indicated maybe subject to change!